Lung cancer is one of the most challenging diseases to diagnose early, with existing screening methods being expensive, invasive, and producing a high rate of false positives. Many cases go undetected until late stages, limiting treatment options and survival rates. There is a growing need for a cost-effective, accurate, and non-invasive diagnostic tool that enables earlier intervention.
This company has developed a breath-based cancer detection technology that identifies disease-specific biomarkers with high accuracy. Unlike traditional CT scans, which often lead to unnecessary procedures, this radiation-free, portable solution offers a more efficient way to screen large populations. By making early detection more accessible, it has the potential to improve patient outcomes and reduce healthcare costs.
With a strong intellectual property portfolio and a growing market demand for better screening solutions, the company is well-positioned to play a key role in the future of cancer diagnostics. Currently raising to advance clinical trials and regulatory approvals, this is an opportunity to invest in a company bringing much-needed innovation to early disease detection.
View the deck through the link below. Some unique identifiers have been removed. For access to detailed materials, please reach to us or your point of contact, as full decks are only shared upon request to maintain confidentiality and exclusivity.
View Pitch Deck